|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
ABITEC is excited to present its latest excipient, CAPMUL GDO, Glycerol Dioleate. CAPMUL GDO is a high-purity, highly versatile functional lipid
|
|
 |
|
We want your experience as a pharmaceutical professional responsible for evaluating and selecting a CMO to be different. This article will help you be prepared when choosing a CMO from among multiple candidates.
|
|
|
|
|
|
|
|
|
Contributor Cindy H. Dubin speaks with some of the leading companies operating in the injectables arena, and discovers this ever-evolving sector is witnessing some very specific and eye-opening trends that are affecting the market’s growth.
|
|
|
Jacob Hunter, Chief Business Officer, ALZpath, Inc., discusses the development and deployment of the company’s proprietary pTau217 antibody, bridging the gap between detection and treatment to improve patient outcomes globally.
|
|
|
Jennifer Gattari explores the key forces driving change in the SI space and outlines the core considerations manufacturers must address to deliver safe, effective therapies at commercial scale and the growing reliance on contract manufacturers to help navigate complexity with confidence.
|
|
|
Donald Kelemen, PhD, says one of the most significant challenges lies in selecting and sourcing the molecules at the heart of LNPs: lipids. The right choices can optimize stability, efficacy, and scalability, while the wrong ones can introduce roadblocks that are difficult (and costly) to overcome.
|
|
|
|
|
|

ProMed Pharma is your distinguished development partner in long-acting injectable and implantable dosage forms. With nearly 20 years of operational history, we have honed our expertise in polymer-based dosage forms, achieving mastery in extended-release dosing. Our proficiency spans molding, extrusion, and microencapsulation techniques, leveraging a diverse spectrum of polymeric excipients encompassing silicones, thermoplastics, and biodegradables. At ProMed Pharma, our commitment to rapid project execution is underpinned by a steadfast dedication to scientific inquiry and technical finesse. Whether you represent an emerging biotech venture or a global pharmaceutical entity, entrust us as your CDMO partner, as we diligently translate scientific concepts into finished dosage forms. Click here for more.
|
|
|
|
|
|
|
|
|
 |
|
In this talk we illustrate several case studies demonstrating how a fundamental understanding of molecular properties combined with a strategic vision for drug product design can lead to effective and advanceable formulations for even the most challenging drug products.
|
|
 |
|
In recent decades, the landscape of parenteral drug production has undergone significant transformation, driven by the emergence of novel molecules and advanced therapies. The pharmaceutical industry has witnessed a notable shift towards biologics, mAbs, and cell-based therapies, which now represent some of the most successful pharmaceutical products globally.
|
|
|
|
|
|
|
|
 |
|
By: Matthias Rischer, PhD, Director Drug Delivery & Innovation Projects, and Jens Morgenthaler, PhD, Managing Director
Introduction
In 2021, the global CDMO market is estimated to be $124 billion and is expected to grow at a CAGR of 7% …
|
|
 |
|
By: Dr. Jens Morgenthaler, General Manager and Dr. Matthias Rischer, Head of Innovation, Losan Pharma GmbH
Introduction
The successful formulation of small molecules is still one of the important challenges of today, especially if these drugs belong to the BioClassificationSystem …
|
|
 |
|
INTRODUCTION
Drug-excipient compatibility testing is one of the early formulation screening steps that can help predict a drug product’s stability. Conventional methods for compatibility testing however, are time consuming, labor intensive, require screening several excipients and eventually different formulations. For …
|
|
|
|
|
|
|
|
|